Johnson & Johnson's Second COVID-19 Vaccine Shot Gives a Strong Boost

Author:
Publish date:
Video Rating:
TV-G
Video Duration:
1

Johnson & Johnson  (JNJ) - Get Johnson & Johnson (JNJ) Report says its COVID-19 vaccine booster shot provides a ‘rapid and robust increase in spike-binding antibodies.’ 

RelatedJohnson & Johnson Stock Gains After Promising COVID Booster Shot Data

The company’s study found a significant increase in binding antibodies in participants between the ages of 18 and 55, and in those 65 years and older who received a lower booster dose.

Related: Who Is Johnson & Johnson's Incoming CEO Joaquin Duato?

"We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine," said Mathai Mammen, Global Head of Janssen Research & Development at Johnson & Johnson. "We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination."

Currently, the Biden administration has offered booster shots only for Pfizer and Moderna  (MRNA) - Get Moderna, Inc. Report, but not for J&J yet.

Related: COVID-19 Vaccine Booster Shots For All Americans Starting September 20

Moderna has also completed its submission for full approval of its COVID-19 vaccine with the FDA. Earlier this week, Pfizer's vaccine was granted full approval. 

Related: FDA Grants Full Approval for Pfizer COVID-19 Vaccine

Related Videos